What was the main driver of Stryker's sales growth in Q2 2025?

Stryker's sales growth in Q2 2025 was primarily driven by an 11.1% increase in net sales, propelled by higher unit volumes across most of its MedSurg and Neurotechnology businesses and the majority of its Orthopaedics businesses. The MedSurg and Neurotechnology segment, in particular, experienced strong growth of 17.3%, partly attributed to the recent acquisition of Inari Medical.

How has the acquisition of Inari Medical impacted Stryker's financial results?

The acquisition of Inari Medical, completed in Q1 2025 for $4,810 million, has significantly boosted the Vascular business within the MedSurg and Neurotechnology segment, contributing to its strong top-line growth. However, the acquisition also led to increased selling, general, and administrative expenses due to integration-related costs, including a charge for vested share-based awards for Inari employees. This impacted the reported operating income margin, though adjusted metrics showed improvement.

What is the outlook for Stryker's profitability given the recent acquisition and increased expenses?

While reported operating income margin saw a slight decrease in Q2 2025 compared to the prior year, primarily due to acquisition-related expenses, Stryker's underlying profitability remains strong as indicated by its adjusted operating income margin, which improved. The company's ability to integrate acquisitions efficiently and manage costs will be key to sustaining profitability. Investors should focus on the growth in adjusted earnings and the strategic benefits of the Inari acquisition as it integrates into Stryker's operations.

How is Stryker managing its debt and liquidity?

Stryker has a strong liquidity position, with current assets significantly exceeding current liabilities. In February 2025, the company entered into a new revolving credit agreement increasing its capacity to $3,000 million. It also issued substantial amounts of senior unsecured notes in February 2025. While debt levels have increased, the company maintains strong investment-grade ratings, enabling it to refinance debt as needed. Cash flow from operations remains robust, supporting its liquidity needs.

SYK 10-Q Quarterly Report Q2 FY2025 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported a solid performance for the second quarter of 2025, with total net sales increasing by 11.1% to $6,022 million compared to the same period in 2024. This growth was driven by robust performance in both the MedSurg and Neurotechnology segment (up 17.3%) and the Orthopaedics segment (up 2.0%), with strong contributions from increased unit volumes across most product lines. Net earnings for the quarter were $884 million, an increase from $825 million in the prior year, resulting in diluted earnings per share of $2.29, up from $2.14. The company made a significant strategic move in the first quarter by completing the acquisition of Inari Medical for $4,810 million, which is expected to bolster its Vascular business. While this acquisition, along with other integration-related costs, impacted operating expenses and the reported operating income margin, the company's adjusted operating income margin showed improvement. Stryker's strong operational execution and strategic acquisitions position it well for continued growth, although investors should monitor the impact of integration costs and macroeconomic factors.

Financial Highlights

52 data points

Beta

Revenue

$6.02B

0.6% Gross Margin

Net Income

$884.00M

0.1% Net Margin

EPS (Diluted)

$2.29

Total Assets

$46.33B

Cash & Equivalents

$2.38B

Free Cash Flow

$928.00M

Financial Statements

Beta

Revenue	$6.02B
Cost of Revenue	$2.18B
Gross Profit	$3.84B
R&D Expenses	$407.00M
SG&A Expenses	$2.08B
Operating Expenses	$2.73B
Operating Income	$1.11B
Interest Expense	$159.00M
Net Income	$884.00M
EPS (Basic)	$2.32
EPS (Diluted)	$2.29
Shares Outstanding (Basic)	382.20M
Shares Outstanding (Diluted)	386.40M

Key Highlights

1Stryker reported a 11.1% increase in net sales for Q2 2025 to $6,022 million, driven by broad-based growth.
2The MedSurg and Neurotechnology segment saw particularly strong growth of 17.3% in net sales, bolstered by the recent acquisition of Inari Medical.
3Net earnings rose to $884 million for the quarter, with diluted EPS increasing to $2.29 from $2.14 in the prior year.
4The company completed a significant acquisition of Inari Medical for $4,810 million in Q1 2025, adding to its Vascular business portfolio.
5Operating income margin decreased to 18.5% from 19.4% due to higher operating expenses, including acquisition and integration costs.
6However, adjusted operating income margin improved, indicating strong underlying operational performance.
7Cash provided by operating activities was $1,361 million for the first six months of 2025, showing a substantial increase from the prior year.

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions